Broad-spectrum β-lactams in obese non-critically ill patients

Nutrition and Diabetes

Volumn 4, Issue JUNE, 2014, Pages

  Hites, M ^a   Taccone, F S ^a   Wolff, F ^a   Maillart, E ^a,b   Beumier, M ^a   Surin, R ^a   Cotton, F ^a   Jacobs, F ^a  

^a ERASME HOSPITAL   (Belgium)

^b BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CEFTAZIDIME; CREATININE; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; BETA LACTAM;

ADULT; AGED; ARTICLE; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; ENTEROBACTERIACEAE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; RISK FACTOR; STAPHYLOCOCCUS; STENOTROPHOMONAS; STREPTOCOCCUS; ANTIBIOTIC THERAPY; BODY MASS; BODY SIZE; NONHUMAN;

EID: 84903728516     PISSN: None     EISSN: 20444052     Source Type: Journal    
DOI: 10.1038/nutd.2014.15     Document Type: Article

References (38)

1. World Health Organization. Obesity. http://www.who.int/topics/obesity/en/ Accessed on 13 June 2013.
2. Janson B, Thursky K. Dosing of antibiotics in obesity. Curr Opin Infect Dis 2012; 25: 634-649.
3. Rich BS, Keel R, Ho VP, Turbendian H, Afaneh CI, Dakin GF et al. Cefepime dosing in the morbidly obese patient population. Obes Surg 2012; 22: 465-471.
4. Newman D, Scheetz MH, Adeyemi OA, Montevecchi M, Nicolau DP, Noskin GA et al. Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual. Ann Pharmacother 2007; 41: 1734-1739.
5. Deman H, Verhaegen J, Willems L, Spriet I. Dosing of piperacillin/ tazobactam in a morbidly obese patient. J Antimicrob Chemother 2012; 67: 782-783.
6. Cheatham SC, Fleming MR, Healy DP, Chung CE, Shea KM, Humphrey ML et al. Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients. Int J Antimicrob Agents 2013; 41: 52-56.
7. Hites M, Taccone FS, Wolff F, Cotton F, Beumier M, De Backer D et al. Case-control study of drug monitoring of b-lactams in obese critically ill patients. Antimicrob Agents Chemother 2013; 57: 708-715.
8. Sturm AW, Allen N, Rafferty KD, Fish DN, Toschlog E, Newell M et al. Pharmacokinetic analysis of Piperacillin administered with Tazobactam in Critically Ill, Morbidly Obese Surgical Patients. Pharmacotherapy 2013; 34: 28-35.
9. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
10. Wolff F, Deprez G, Seyler L, Taccone FS, Hites M, Gulbis B et al. Rapid quantification of six beta-lactams to optimize dosage regimens in severely septic patients. Talanta 2013; 103: 153-160.
11. Mouton JW, Brown DF, Apfalter P, Canton R, Giske CG, Ivanova M et al. The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: The EUCAST approach. Clin Microbiol Infect 2012; 18: E37-E45.
12. Taccone FS, Cotton F, Roisin S, Vincent JL, Jacobs F. Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother 2012; 56: 2129-2131.
13. Drusano GL, Hutchison M. The pharmacokinetics of meropenem. Scand J Infect Dis 1995; 96(Suppl 1): 11-16.
14. Sorgel F, Kinzig M. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J Antimicrob Chemother 1993; 31(Suppl A): 39-60.
15. Crandon JL, Bulik CC, Kuti JL, Nicolau DP. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010; 54: 1111-1116.
16. Paulfeuerborn W, Müller HJ, Borner K, Koeppe P, Lode H. Comparative pharmacokinetics and serum bactericidal activities of SCE-2787 and ceftazidime. Antimicrob Agents Chemother 1993; 37: 1835-1841.
17. European Committee on Antimicrobial Susceptibility Testing. Clinical breakpoints- bacteria http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST- files/Breakpoint-tables/Breakpoint-table-v-2.0-120221.pdf. Accessed on 14 July 2013.
18. Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 2004; 58: 119-133.
19. Hayashi Y, Roberts JA, Paterson DL, Lipman J. Pharmacokinetic evaluation of piperacillin-tazobactam. Expert Opin Drug Metab Toxicol 2010; 6: 1017-1031.
20. Bulitta JB, Duffull SB, Kinzig-Schippers M, Holzgrabe U, Stephan U, Drusano GL et al. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 2007; 51: 2497-2507.
21. Mouton JW, Horrevorts AM, Mulder PG, Prens EP, Michel MF. Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers. Antimicrob Agents Chemother 1990; 34: 2307-2311.
22. Barbhaiya RH, Forgue ST, Gleason CR, Knupp CA, Pittman KA, Weilder DJ et al. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob Agents Chemother 1992; 36: 552-557.
23. Nilsson-Ehle I, Hutchison M, Hawarth SJ, Norrby SR. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males. Eur J Clin Microbiol Infect Dis 1991; 10: 85-88.
24. Bax RP, Bastain W, Featherstone A, Wilkinson DM, Hutchinson M, Haworth SJ. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother 1989; 24(Suppl A): 311-320.
25. Zakrison TL, Hille DA, Namias N. Effect of body mass index on treatment of complicated intra-abdominal infections in hospitalized adults: comparison of ertapenem with piperacillin-tazobactam. Surg Infect (Larchmt) 2012; 13: 38-42.
26. Barbour A, Schmidt S, Rout WR, Ben-David K, Burkhardt O, Derendorf H. Soft tissue penetration of cefuroxime determined by clinical microdialysis in morbidly obese patients undergoing abdominal surgery. Int J Antimicrob Agents 2009; 34: 231-235.
27. Craig WA, Redington J, Ebert SC. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 1991; 27(Suppl C): 29-40.
28. Mouton JW, Punt N, Vinks AA. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit. Clin Ther 2005; 27: 762-772.
29. Drusano GL, Liu W, Kulawy R, Louie A. Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrob Agents Chemother 2011; 55: 5300-5305.
30. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: Implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010; 49: 1-16.
31. Claus BO, Hoste EA, Colpaert K, Robays H, Decruyenaere J, De Waele JJ. Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy. J Crit Care 2013; 28: 695-700.
32. Bosma RJ, Krikken JA, Homan van der Heide JJ, de Jong PE, Navis GJ. Obesity and renal hemodynamics. Contrib Nephrol 2006; 151: 184-202.
33. Salazar DE, Corcoran GB. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med 1988; 84: 1053-1060.
34. Chew-Harris JSC, Florkowski CM, George PM, Elmslie JL, Endre ZH. The relative effects of fat muscle mass on cystatin C and estimates of renal function in healthy young men. Ann Clin Biochem 2013; 50: 39-46.
35. Dionne RE, Bauer LA, Gibson GA, Griffin WO, Blouin RA. Estimating creatinine clearance in morbidly obese patients. Am J Hosp Pharm 38: 841-844.
36. Demirovic JA, Pai AB, Pai MP. Estimation of creatinine clearance in morbidly obese patients. Am J Health-Syst Pharm 2009; 66: 642-648.
37. Blouin R, Bauer L, Miller D, Record K, Griffen W. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982; 21: 575-580.
38. Grace E. Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years. J Antimicrob Chemother 2012; 67: 1305-1310.